CD154 Antibody (TRAP1): sc-19985
- CD154 Antibody (TRAP1) is a mouse monoclonal IgG1 κ, cited in 4 publications, provided at 200 µg/ml
- raised against CD40 ligand expressed on CV-1 cells of human origin
- recommended for detection of CD154 of human origin by IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also provided azide-free for blocking, sc-19985 L, 200 µg/0.1 ml
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD154 Antibody (TRAP1). These reagents are now offered in bundles with CD154 Antibody (TRAP1) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD154 Antibody (TRAP1) is a mouse monoclonal IgG1 antibody that detects CD154 in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD154, also known as CD40 ligand, plays a crucial role in the immune response by facilitating communication between T cells and B cells, which is essential for effective antibody production. CD154 is primarily located on the surface of activated T cells, where CD154 interacts with CD40 on B cells, triggering a cascade of signaling events that lead to B cell activation, proliferation, and differentiation into antibody-secreting plasma cells. This interaction not only promotes immunoglobulin class switching but also enhances the overall adaptive immune response. Dysregulation of CD154 expression can lead to various immunological disorders, including hyper-IgM immunodeficiency syndrome type 1, highlighting CD154′s significance in maintaining immune homeostasis. Anti-CD154 antibody (TRAP1) serves as an invaluable tool for researchers studying T cell and B cell interactions, immune signaling pathways, and the underlying mechanisms of immune-related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD154 Antibody (TRAP1) References:
- CD154 transcriptional regulation in primary human CD4 T cells. | Cron, RQ. 2003. Immunol Res. 27: 185-202. PMID: 12857968
- The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. | Toubi, E. and Shoenfeld, Y. 2004. Autoimmunity. 37: 457-64. PMID: 15621572
- CD154 and its receptors in inflammatory vascular pathologies. | Hassan, GS., et al. 2009. Trends Immunol. 30: 165-72. PMID: 19282242
- The role of CD154 in haematopoietic development. | Seijkens, T., et al. 2010. Thromb Haemost. 104: 693-701. PMID: 20694278
- Role of CD154 in cancer pathogenesis and immunotherapy. | Hassan, GS., et al. 2015. Cancer Treat Rev. 41: 431-40. PMID: 25843228
- Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. | Pinelli, DF. and Ford, ML. 2015. Immunotherapy. 7: 399-410. PMID: 25917630
- Update on CD40 and CD154 blockade in transplant models. | Zhang, T., et al. 2015. Immunotherapy. 7: 899-911. PMID: 26268734
- Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis. | Lai, JH., et al. 2019. Cells. 8: PMID: 31426619
- Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis. | Hassan, GS., et al. 2022. Cells. 11: PMID: 35681441
- Implications of CD154 and Its Receptors in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. | Allard, CC., et al. 2024. Cells. 13: PMID: 39404385
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD154 Antibody (TRAP1) | sc-19985 | 200 µg/ml | $316.00 | |||
CD154 Antibody (TRAP1): m-IgG Fc BP-HRP Bundle | sc-536633 | 200 µg Ab; 10 µg BP | $354.00 | |||
CD154 Antibody (TRAP1): m-IgGκ BP-HRP Bundle | sc-533790 | 200 µg Ab; 40 µg BP | $354.00 | |||
CD154 Antibody (TRAP1): m-IgG1 BP-HRP Bundle | sc-544720 | 200 µg Ab; 20 µg BP | $354.00 | |||
CD154 Antibody (TRAP-1) FITC | sc-19985 FITC | 200 µg/ml | $330.00 | |||
CD154 Antibody (TRAP-1) L | sc-19985 L | 200 µg/0.1 ml | $316.00 | |||
CD154 Antibody (TRAP-1) PE | sc-19985 PE | 200 µg/ml | $343.00 |